Grifols · 11 hours ago
Senior Pricing Analyst
Grifols is a global healthcare company that since 1909 has been working to improve the health and well-being of people around the world. The Senior Pricing Analyst will support the plasma procurement pricing functions by setting fees for plasma donation centers and analyzing market dynamics to ensure competitive pricing strategies.
BiotechnologyHealth CareManufacturing
Responsibilities
Support the design and implementation of advanced pricing strategies for plasma procurement, ensuring alignment with global business objectives and market competitiveness
Perform advanced analysis of pricing trends, market data, and competitive intelligence to identify opportunities, risks, and recommend actions
Provide data-driven insights and recommendations to senior leadership on pricing strategies and market positioning
Collaborate with global and regional teams to ensure alignment and consistency in pricing frameworks and governance
Monitor and interpret pricing performance metrics and compliance, preparing clear reports and dashboards for stakeholders
Lead complex analytical projects and initiatives that impact pricing, procurement, and promotional efforts
Support ad hoc pricing projects and initiatives as needed
Qualification
Required
Bachelor's degree in Economics, Business, Finance, Engineering Math, or a related field
Minimum 8 years of experience, with at least +3 years in pricing, financial analysis, or business analytics, preferably in the pharmaceutical or healthcare industry
Strong analytical skills and proficiency in Excel, Power BI, and data visualization tools
Knowledge of SQL, Python, and other programming languages is highly valued
Excellent communication and stakeholder management skills
Fluent in English
Preferred
Master's degree is a plus
Additional languages are a plus
Company
Grifols
Grifols is a global healthcare company.
Funding
Current Stage
Public CompanyTotal Funding
$2.51BKey Investors
Michael J. Fox Foundation
2025-01-14Grant· $21M
2024-06-04Post Ipo Debt· $1.41B
2024-04-23Post Ipo Debt· $1.07B
Leadership Team
Recent News
2025-12-24
Pharma Letter
2025-11-28
2025-11-19
Company data provided by crunchbase